Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-02-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/9781118098141.CH8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Selectively nonselective kinase inhibition: striking the right balance.

  2010cited by this paper
• Axitinib (AG-013736).

  2010cited by this paper
• ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

  2009cited by this paper
• Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

  2009cited by this paper
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

  2009cited by this paper
• Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

  2009cited by this paper
• Phase II trial of sorafenib in metastatic thyroid cancer.

  2009cited by this paper
• Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer

  2008cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

  2008cited by this paper
• Antiangiogenic therapy in malignant gliomas

  2008cited by this paper
• The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer

  2007cited by this paper
• Molecular basis for sunitinib efficacy and future clinical development

  2007cited by this paper
• Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

  2007cited by this paper
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

  2007cited by this paper
• AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

  2007cited by this paper
• Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer

  2007cited by this paper
• Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

  2007cited by this paper
• Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

  2007cited by this paper
• Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.

  2007cited by this paper
• Defining clinically relevant molecular subsets of lung cancer

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

  2006cited by this paper
• Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

  2006cited by this paper
• Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis

  2006cited by this paper
• Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors

  2006cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Sunitinib malate for the treatment of solid tumours: a review of current clinical data

  2006cited by this paper
• The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

  2006cited by this paper
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

  2006cited by this paper
• Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

  2005cited by this paper
• Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes

  2005cited by this paper
• Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks

  2005cited by this paper
• VEGF as a Key Mediator of Angiogenesis in Cancer

  2005cited by this paper
• Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.

  2005cited by this paper
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• Stromal fibroblasts in cancer initiation and progression

  2004cited by this paper
• RNA interference for the identification of disease-associated genes.

  2004cited by this paper
• TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia

  2004cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.

  2004cited by this paper
• A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

  2004cited by this paper
• Infectious agents and cancer: criteria for a causal relation.

  2004cited by this paper
• Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Treating cancer's kinase 'addiction'

  2004cited by this paper
• Up-Regulation of Matrix Metalloproteinase-9 in T Lymphocytes of Mammary Tumor Bearers: Role of Vascular Endothelial Growth Factor 1

  2003cited by this paper
• Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.

  2003cited by this paper
• Tumor vascularity and tryptase‐positive mast cells correlate with a poor prognosis in melanoma

  2003cited by this paper
• Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

  2003cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Matrix metalloproteinases in tumor-host cell communication.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

  2001cited by this paper
• Induction of matrix metalloproteinase-1 (MMP-1) during epidermal invasion of the stroma in human skin organ culture: keratinocyte stimulation of fibroblast MMP-1 production

  2001cited by this paper
• Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

  2000cited by this paper
• Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.

  2000cited by this paper
• MMP-9 Supplied by Bone Marrow – Derived Cells Contributes to Skin Carcinogenesis

  2000cited by this paper
• Signaling—2000 and Beyond

  2000cited by this paper
• Genetic instabilities in human cancers

  1998cited by this paper
• Suppression of Ki‐ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki‐ras mutation but not those without Ki‐ras mutation

  1997cited by this paper
• Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.

  1996cited by this paper
• The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

  1996cited by this paper
• erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

  1994cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

  1993cited by this paper

• Effective alternative strategies to combat challenges associated with MDR bacterial infections: Drug repurposing, role of artificial intelligence, and novel therapeutic options.

  2025cites this paper
• Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance.

  2023cites this paper
• Genie in a bottle: controlled release helps tame natural polypharmacology?

  2019cites this paper
• Attractor – a new turning point in drug discovery

  2019cites this paper
• DDDT_A_216397 2957..2968

  2019cites this paper
• Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery

  2018cites this paper
• FD5180, a Novel Protein Kinase Affinity Probe, and the Effect of Bead Loading on Protein Kinase Identification

  2017cites this paper
• A Novel Class of Hsp90 C‐Terminal Modulators Have Pre‐Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response

  2016cites this paper
• Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.

  2016cites this paper
• Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs

  2016cites this paper
• Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system.

  2014cites this paper
• Predictive in silico off-target profiling in drug discovery.

  2014cites this paper
• Polypharmacology - foe or friend?

  2013cites this paper